IDEXX Laboratories, Inc. $IDXX Shares Sold by Railway Pension Investments Ltd

Railway Pension Investments Ltd reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 82.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,360 shares of the company’s stock after selling 211,120 shares during the quarter. Railway Pension Investments Ltd owned 0.06% of IDEXX Laboratories worth $23,879,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. J.Safra Asset Management Corp purchased a new position in IDEXX Laboratories in the 2nd quarter valued at $25,000. SHP Wealth Management purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $26,000. Elevation Wealth Partners LLC grew its holdings in shares of IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after buying an additional 32 shares in the last quarter. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at about $26,000. Finally, WealthCollab LLC purchased a new position in shares of IDEXX Laboratories in the second quarter worth about $30,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on IDXX. Citigroup upped their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. UBS Group boosted their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Barclays reduced their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $747.00.

IDEXX Laboratories Stock Up 0.3%

IDXX stock opened at $556.69 on Tuesday. The firm has a market cap of $43.86 billion, a PE ratio of 39.15, a PEG ratio of 2.96 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The firm’s 50 day moving average price is $559.23 and its 200-day moving average price is $572.70. IDEXX Laboratories, Inc. has a one year low of $518.55 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping the consensus estimate of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the prior year, the business posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.